This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Enzon Announces The Initiation Of Two Phase I Studies In Collaboration With The National Cancer Institute

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute (NCI), for two of the Company’s novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38). Both EZN-2968 and EZN-2208 have been shown to down-modulate HIF-1α, a subunit of HIF-1. HIF-1 is frequently overexpressed in cancer cells, where it is involved in the upregulation of gene products essential for tumor invasion, migration, angiogenesis and production of vascular endothelial growth factor (VEGF). The studies are being sponsored by the NCI under Clinical Trials Agreements with Enzon.

The first study will explore the safety and effectiveness of EZN-2968, an LNA-based antisense oligonucleotide, in patients with solid malignancies predominantly involving the liver. The second study will explore the modulation of HIF-1α in solid tumors after treatment with EZN-2208 combined with Avastin® (bevacizumab, Genentech/Roche), a humanized antibody targeting VEGF-A. Anti-angiogenic agents such as Avastin have limited efficacy, potentially as a result of the induction and up-regulation of hypoxia-inducible factors such as HIF-1α in the hypoxic conditions of the post-treatment tumor. Such effects may be offset by treatment with ENZ-2208, a topoisomerase inhibitor that down regulates HIF-1α in addition to having a cytotoxic effect.

“HIF-1α is a key element of the signaling cascade that promotes tumor growth and metastases in a wide range of cancers,” said Ivan Horak, MD, Enzon’s President of Research and Development and Chief Scientific Officer. “These two Phase I studies build on a growing body of clinical and preclinical evidence demonstrating the potential of both EZN-2968 and EZN-2208 to inhibit this important target. We look forward to collaborating with the NCI in further understanding the promise demonstrated by these two product candidates.”

The EZN-2968 study is expected to enroll 22 patients with solid tumors, predominantly involving the liver. EZN-2968 will be administered as a two-hour intravenous infusion once a week for three consecutive weeks, followed by a three-week period without drug. Tumor biopsies and other correlative imaging and pharmacodynamic studies will be performed at baseline and after drug administration.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs